/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

I

Iveta Kudaba

Riga Aeronautical Institute(LV)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

43

Papers

12.7K

Citations

19

h-index

21

i10-index

Iveta Kudaba is an academic researcher from Riga Aeronautical Institute. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Gastric Cancer Management and Outcomes & Lung Cancer Treatments and Mutations. The author has an h-index of 19, co-authored 37 publications.

Research Topics

Cancer Immunotherapy and Biomarkers Gastric Cancer Management and Outcomes Lung Cancer Treatments and Mutations Gastrointestinal Tumor Research and Treatment Cancer Genomics and Diagnostics

Papers by this author

works

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

2019 · The Lancet · 3,270 citations

https://doi.org/10.1016/s0140-6736(18)32409-7

Tony Mok Yi‐Long Wu Iveta Kudaba Dariusz M. Kowalski

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

2019 · The Lancet · 3,270 citations

https://doi.org/10.1016/s0140-6736(18)32409-7

Tony Mok Yi‐Long Wu Iveta Kudaba Dariusz M. Kowalski

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

2020 · The Lancet Oncology · 865 citations

https://doi.org/10.1016/s1470-2045(19)30863-0

Sandra M. Swain David Miles Sung‐Bae Kim Young‐Hyuck Im

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial

2018 · BMC Cancer · 27 citations

https://doi.org/10.1186/s12885-018-4283-z

Zsolt Markóczy Veronika Sárosi Iveta Kudaba Gabriella Gálffy

Research topics

topics

Cancer Immunotherapy and Biomarkers

Gastric Cancer Management and Outcomes

Lung Cancer Treatments and Mutations

Gastrointestinal Tumor Research and Treatment

Cancer Genomics and Diagnostics

Chat about Author

Papers

Chat

Click to start Chat